An observational study in Melanoma (Skin Cancer) and Skin Carcinoma, sponsored by Centre Hospitalier Universitaire Henri Mondor, Assistance Publique Hôpitaux de Paris. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Centre Hospitalier Universitaire Henri Mondor, Assistance Publique Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Skin palpation remains, alongside visual inspection, the main clinical tool used to detect cutaneous abnormalities. However, palpation is a subjective, operator-dependent examination with limited sensitivity. There is currently no simple, real-time, low-cost, non-invasive tool available in routine clinical practice to objectively characterize the mechanical properties of skin tissue.
The Impact-Based Analysis Method (IBAM) is a non-invasive biomechanical characterization technique developed by the MSME laboratory (Modélisation et Simulation Multi-Échelle, Université Paris Est Créteil) and the Mondor Institute for Biomedical Research (IMRB). It measures the mechanical response of soft tissue to a small mechanical impact, producing a quantitative indicator (Δt) that reflects local tissue stiffness. The reproducibility and sensitivity of this method have previously been demonstrated in preclinical models.
This study aims to evaluate whether IBAM can distinguish malignant cutaneous tumors (basal cell carcinoma, squamous cell carcinoma, melanoma) from healthy surrounding skin based on their mechanical properties, and to characterize how these mechanical properties evolve from the tumor center toward clinically healthy margins.
This is a prospective, single-center, ex vivo cohort study conducted at the Department of Plastic Surgery, Henri Mondor University Hospital (AP-HP), France. Patients undergoing surgical excision (with margins) for a suspected malignant cutaneous tumor will be included. Immediately after surgical excision, and before the specimen is sent for standard pathological examination, IBAM measurements will be performed ex vivo at three locations on the surgical specimen: the center of the tumor, the near peri-lesional area, and the distant peri-lesional area (presumed healthy margin). This additional step does not modify the patient's usual surgical or diagnostic management and does not require any additional intervention on the patient.
The primary objective is to compare the IBAM-derived mechanical indicator (Δt) between malignant tissue and healthy tissue, using paired measurements from the same surgical specimen. The secondary objective is to describe the progressive change in mechanical properties from the tumor center to the healthy margin, which may help define more objective surgical safety margins in the future.
A total of 10 patients will be included, based on a sample size calculation for a paired comparison (α = 5%, power = 80%). Statistical analysis will use paired Student's t-test or Wilcoxon signed-rank test, depending on data distribution (assessed by Shapiro-Wilk test).
This research does not fall under the French "Loi Jardé" framework for research involving the human person, as it involves no additional intervention beyond standard care. It complies with the CNIL reference methodology MR-004. Patients receive individual written information and provide written consent or non-opposition prior to inclusion. Data are pseudonymized and securely stored.
If confirmed, this method could provide surgeons with a simple, rapid, and objective tool to help differentiate malignant from healthy skin tissue intraoperatively, and to better define resection margins, with the ultimate goal of improving the surgical management of cutaneous malignancies.
Background and Rationale
Skin cancer is among the most frequent malignancies worldwide, and its incidence continues to rise. Early and accurate identification of tumor margins is essential both for diagnosis and for surgical planning, since incomplete excision increases the risk of local recurrence while unnecessarily wide excision increases morbidity, particularly in cosmetically or functionally sensitive areas.
In current clinical practice, the assessment of cutaneous lesions relies primarily on visual inspection and manual palpation. Palpation, in particular, is used empirically by clinicians to estimate tissue consistency and to help delineate the boundaries of a lesion. However, this examination is entirely subjective, strongly dependent on the experience of the examiner, and lacks any quantitative or reproducible basis. No simple, real-time, low-cost, non-invasive device is currently available in routine clinical practice to objectively characterize the mechanical properties of skin tissue and to assist clinicians in distinguishing pathological from healthy tissue.
Cutaneous tumors are known to exhibit altered biomechanical properties compared with healthy skin, reflecting changes in tissue composition, cellular density, and extracellular matrix organization. Several imaging and mechanical characterization techniques (elastography, indentation testing, suction devices) have been investigated to quantify these differences, but most require bulky equipment, are time-consuming, or are not adapted to intraoperative or bedside use.
The Impact-Based Analysis Method (IBAM) is a non-invasive, low-cost mechanical characterization technique developed collaboratively by the MSME laboratory (Modélisation et Simulation Multi-Échelle, UMR CNRS 8208, Université Paris Est Créteil) and the Mondor Institute for Biomedical Research (IMRB). The method relies on delivering a small, calibrated mechanical impact to the tissue surface and recording the resulting impactor motion. From this signal, a quantitative indicator (denoted Δt, corresponding to the time interval between successive impactor rebounds) is derived, which reflects the local stiffness and viscoelastic behavior of the underlying tissue. The device is portable, produces results in real time, requires no specific consumables, and involves no radiation or invasive procedure. Its reproducibility, spatial resolution, and sensitivity to changes in tissue mechanical properties have previously been established in preclinical (murine) models, including models of cutaneous neurofibromatosis.
Building on this preliminary work, the investigators hypothesize that IBAM measurements can discriminate malignant cutaneous tumor tissue from adjacent healthy skin, and that the mechanical signal progressively normalizes when measured at increasing distance from the tumor center. If confirmed, this would support the development of IBAM as a practical adjunct tool for intraoperative assessment of surgical margins.
Objectives
Primary objective: To determine whether malignant cutaneous tumor tissue (basal cell carcinoma, squamous cell carcinoma, or melanoma) can be differentiated from healthy cutaneous tissue based on mechanical properties measured by IBAM, using the Δt indicator as the primary outcome.
Secondary objective: To characterize the spatial evolution of the biomechanical signal from the center of the tumor toward increasingly distant peri-lesional areas, in order to explore the potential of IBAM to help define objective surgical safety margins.
Study Design
This is a prospective, single-center, ex vivo cohort study conducted within the Department of Plastic, Reconstructive and Aesthetic Surgery at Henri Mondor University Hospital (Assistance Publique - Hôpitaux de Paris, AP-HP), France. The study does not fall within the scope of the French law on research involving the human person ("Loi Jardé"), as it involves no modification of, or addition to, the patient's standard diagnostic or surgical care pathway. All measurements are performed ex vivo, directly on the surgical specimen, after excision and before transmission to the pathology department.
Study Population
Eligible patients are adults followed in the Department of Plastic Surgery at Henri Mondor University Hospital who present with a cutaneous lesion clinically or dermoscopically suspicious for malignancy (basal cell carcinoma, squamous cell carcinoma, or melanoma) and for whom surgical excision with safety margins is indicated as part of standard care.
Non-inclusion criteria:
Melanoma for which diagnostic excision has already been performed in sano prior to inclusion Cutaneous tumor related to a virally transmissible infection Ulcerated or fungating ("ulcéro-bourgeonnante") tumor
Based on a sample size calculation for a paired comparison design (two-sided alpha = 5%, statistical power = 80%), a total of 10 patients will be included. Recruitment is expected at a rate of approximately 2 to 6 patients per month, over an estimated inclusion period of 6 to 12 months.
Study Procedures
Patients meeting eligibility criteria are identified during routine dermato-plastic surgical consultation. Individual written information about the study is provided at the time of hospitalization (the day before or the day of surgery), and the patient's written consent or non-opposition is collected and documented, in accordance with the CNIL reference methodology MR-004.
Surgery proceeds according to the standard of care, with excision of the tumor and the surgically indicated safety margins. Immediately after excision, and before the specimen is transferred to the pathology laboratory for standard histological analysis, ex vivo IBAM measurements are performed directly on the surgical specimen at three predefined locations:
The center of the macroscopically visible tumor (malignant zone) The near peri-lesional area, close to the tumor edge The distant peri-lesional area, corresponding to the clinically healthy surgical margin
Measurements are recorded on a paper case report form at the time of testing, then transcribed the same day onto a secured, password-protected Excel file; the paper source is then destroyed. This additional ex vivo measurement step is performed without altering the specimen, without delaying or modifying its transmission to the pathology department beyond a negligible interval (estimated at less than one hour before fixation in formalin), and without any impact on the patient's subsequent management. The nature of the suspected tumor (from the pre-operative consultation report) and the final histopathological diagnosis (nature of the tumor, completeness of excision) are subsequently extracted from the institutional electronic medical record (ORBIS).
Outcome Measures
Primary endpoint: Variation of the Δt indicator (derived from the IBAM signal) between the malignant tumor zone and the healthy peri-lesional zone, measured on paired samples from the same surgical specimen.
Secondary endpoint: Trend of the Δt indicator across the three measurement locations (tumor center, near margin, distant margin), describing the spatial gradient of mechanical properties from the lesion to healthy tissue.
Statistical Analysis
The normality of data distribution will first be assessed using the Shapiro-Wilk test. Paired comparisons between the malignant and healthy zones will then be performed using the paired Student's t-test if data are normally distributed, or the Wilcoxon signed-rank test otherwise. A two-sided p-value below 0.05 will be considered statistically significant.
Data Management and Confidentiality
Personal data are collected exclusively from the patient's medical record (consultation report and histopathology results, via the institutional ORBIS system) and from the dedicated ex vivo mechanical measurements performed for the study. No data from the French National Health Data System (SNDS) are used. Data are pseudonymized using a patient identification number; the correspondence table linking this number to patient identity is accessible only to the coordinating investigator and the scientific lead. Pseudonymized data are stored on a password-protected Excel file, on a password-protected computer, in a locked office at Henri Mondor University Hospital. Data will be retained for 2 years. This research complies with Regulation (EU) 2016/679 (GDPR) and with the CNIL reference methodology MR-004 for studies not involving the human person.
Ethical and Regulatory Aspects
The study has been submitted for review to the Ethics Committee (IRB) of Henri Mondor University Hospitals. The sponsor (responsable de traitement) is Assistance Publique - Hôpitaux de Paris (AP-HP), represented by the Délégation à la Recherche Clinique et à l'Innovation (DRCI); the coordinating investigator (responsable de la mise en œuvre) is the physician responsible for the scientific conduct and data handling of the study within the Department of Plastic Surgery at Henri Mondor University Hospital.
Expected Significance
By providing a simple, real-time, low-cost, and non-invasive means of objectively characterizing the mechanical properties of cutaneous tissue, this study may contribute to the development of a practical adjunct tool for surgeons to help differentiate malignant from healthy skin tissue and to support more objective, standardized definition of surgical resection margins - ultimately aiming to improve the diagnostic and therapeutic management of patients with cutaneous malignancies.
3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.
This study's planned enrollment of 10 is below the median of 187 across 489 observational studies indexed under Melanoma.
Browse Melanoma studies →This is the only study on the registry with Centre Hospitalier Universitaire Henri Mondor, Assistance Publique Hôpitaux de Paris as lead sponsor.
Counted across the registry records on this site, refreshed daily.
The study population consists of adult patients followed in the Department of Plastic, Reconstructive and Aesthetic Surgery at Henri Mondor University Hospital (AP-HP), France, who present with a cutaneous lesion clinically or dermoscopically suspicious for malignancy (basal cell carcinoma, squamous cell carcinoma, or melanoma) and for whom surgical excision with safety margins is indicated as part of standard care. Patients are identified during routine dermato-plastic surgical consultation ("carrefour dermatoplastique"). A total of 10 patients will be included at a single center, with an expected recruitment rate of approximately 2 to 6 patients per month.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with a suspected malignant cutaneous tumor (basal cell carcinoma, squamous cell carcinoma, or melanoma) undergoing surgical excision with safety margins at the Department of Plastic Surgery, Henri Mondor University Hospital. Immediately after excision, ex vivo biomechanical measurements are performed on the surgical specimen using the Impact-Based Analysis Method (IBAM) at three locations: the tumor center (malignant zone), the near peri-lesional area, and the distant peri-lesional area (healthy margin). No additional intervention is performed on the patient; standard surgical and pathological management is unchanged. Paired measurements from the same specimen are compared to assess whether IBAM can differentiate malignant from healthy cutaneous tissue based on mechanical properties, and to characterize how these properties evolve from the tumor toward healthy margins.
Difference in the IBAM mechanical indicator (Δt) between malignant tumor tissue and healthy peri-lesional tissue
For each included surgical specimen, the IBAM indicator Δt (time interval between successive impactor rebounds, reflecting local tissue stiffness) is measured ex vivo at the center of the malignant tumor and at the distant peri-lesional area (clinically healthy margin). The paired difference in Δt between these two zones is calculated for each patient and compared across the cohort, to determine whether malignant and healthy cutaneous tissue can be mechanically differentiated using this indicator.
Time frame: Measured on the day of surgery (ex vivo, immediately after surgical excision)
Spatial gradient of the IBAM mechanical indicator (Δt) from the tumor center to the healthy surgical margin
For each included surgical specimen, the IBAM indicator Δt is measured ex vivo at three predefined locations: the center of the malignant tumor, the near peri-lesional area, and the distant peri-lesional area (healthy margin). The progression of Δt values across these three zones is described for each patient and across the cohort, in order to characterize how tissue mechanical properties evolve from the tumor toward healthy tissue, and to explore the potential of this gradient to help define objective surgical safety margins.
Time frame: Measured on the day of surgery (ex vivo, immediately after surgical excision)
No study locations are listed for this record.
Plan to share: No — Individual participant data will not be shared outside the investigator team. This is a small, single-center, exploratory study (n=10) using pseudonymized data with restricted access, in accordance with the information provided to participants at the time of consent. Aggregated, de-identified results will be made available through scientific publication.
Start is estimated for Dec 2026; primary completion for Dec 2027, 11 months later.
Of 177 non-industry observational studies under Melanoma, half reached primary completion within 178 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 320. This study's planned 11 months is below that.
Counting every sponsor, half of 236 studies reached it within 71 months; a quarter within 35 and three quarters within 248.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.